FDA Broadens Clearance For Agendia’s MammaPrint(R)

	Tweet

Agendia, a world leader in molecular cancer diagnostics, announced that the US Food and Drug Administration (FDA) cleared its MammaPrint breast cancer recurrence test for all ages. MammaPrint is the only FDA-cleared breast cancer recurrence test available to patients and physicians. Over the past three years, the FDA has issued four clearances for MammaPrint, covering all aspects of this important service.

“This FDA clearance, along with our recently obtained CMS coverage for all stage I and II breast cancer patients, including patients with up to three positive lymph nodes, will facilitate our discussions with healthcare providers about patients’ eligibility criteria for MammaPrint,” said Dr. Bernhard Sixt, Agendia’s Chief Executive Officer.

“This new clearance confirms the opinion of the international medical community that MammaPrint carries clinical utility and is safe and effective in breast cancer patients of all ages,” said Dr. Richard Bender, Chief Medical Officer of Agendia.

"Seeking clearance for all ages further demonstrates Agendia’s commitment to provide patients and physicians with high quality FDA-cleared tests to help guide vital treatment decisions.” In Europe, MammaPrint has been approved for all ages since 2004.

About MammaPrint(R)

MammaPrint is the first and only breast cancer recurrence test cleared by the U.S. Food and Drug Administration (FDA).FDA clearance under the in vitro diagnostic multivariate index assay (IVDMIA) guidelines requires clinical and analytical validation and reporting systems to ensure patient safety issues are addressed. Highly accurate, MammaPrint identifies patients with early metastasis risk patients who are likely to develop metastases within five years following surgery. Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk. In planning treatment, the MammaPrint test results provide doctors with a clear rationale to assess the benefit of chemotherapy in addition to other clinical information and pathology tests.

All MammaPrint tests are conducted in Agendia’s CLIA-accredited service laboratory. Breast cancer recurrence assays currently marketed by other manufacturers have not been subject to the rigorous FDA clearance process.

About Agendia

Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting-edge genomics platform for tumor gene expression profiling, the company’s tests help physicians more accurately tailor cancer treatments. Agendia markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands.

Source: Agendia B.V

RELATED STORIES:
Detecting breast cancer’s fingerprint in a droplet of blood   Breast cancer drug extends lives: study   Breast cancer outcome similar in women and men   DCIS patients who get invasive breast cancer have higher mortality   Scientists Discover New Therapeutic Target for Some Breast Cancers   Strenuous exercise lowers lifetime breast cancer risk   Falling breast cancer rates seen only in whites   Got stress? It could impact breast cancer recurrence   Study examines risk factors for cancer in unaffected breast of breast cancer patients   Vegetables tied to lower breast cancer risk   Breast cancer regimen linked to cognitive decline   Exercise Improves Quality of Life for People with Breast Cancer   New breast cancer gene may help predict risk   Watercress may ‘turn off’ breast cancer signal   Men Can Get Breast Cancer, Too: Students Launch Alliance to Raise Awareness Among Both Genders   Breast cancer and heart disease may have common roots   Validation of a tool for identifying women at high risk for hereditary breast cancer   Big Bias In Who Gets Screened for Breast Cancer   Study Examines Mastectomy And Breast-conserving Surgery Rates   Novel imaging technique may reduce lymphedema in breast cancer patients   Gene acts as a brake on breast cancer progression   Scientists Identify Gene in Breast Cancer Pathway

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]